Global Laboratory Proficiency Testing Market Report 2024: A $2.13 Billion Market by 2030, Expanding at a CAGR of 6.6% from 2024 to 2030

Laboratory Proficiency Testing Market

The “Global Laboratory Proficiency Testing Market Size, Share & Trends Analysis Report by Industry (Clinical Diagnostics, Cannabis), Technology (Cell Culture, PCR), End-use (CROs, Hospitals), Region, and Segment Forecasts, 2024-2030″ report has been added to ResearchAndMarkets.com’s offering.

The global laboratory proficiency testing market size is expected to reach USD 2.13 billion by 2030, expanding at a CAGR of 6.6% from 2024 to 2030.

End-use industries, such as healthcare, environmental, food, and pharmaceuticals, are subject to strict regulatory requirements and accreditation standards, which is anticipated to drive the demand for laboratory proficiency testing in the coming years.

Moreover, participating in proficiency testing programs helps laboratories demonstrate compliance with these standards and regulatory bodies, ensuring the accuracy and reliability of their evaluating procedures, thereby contributing to the growth of the overall market.

Laboratory Proficiency Testing Market Report Highlights

  • Based on industry, the clinical diagnostic segment held the largest revenue share in 2023 due to the widespread adoption of proficiency testing to keep clinical diagnostic test results reliable and high-quality
  • The cell culture technology segment held the largest revenue share in 2023 owing to its wide usage in identifying contagious microorganisms in different applications
  • The hospitals end-use segment dominated the market in 2023. However, the contract research organizations (CROs) segment is expected to register the fastest CAGR from 2024 to 2030 due to the increasing demand for outsourcing services in the healthcare sector
  • North America held the largest share of 43.78% in 2023 due to the presence of well-established players, developed pharmaceutical & diagnostics industries, and high adoption of laboratory proficiency test
  • Key players operating in the market constantly focus on product launches, partnerships, and geographical expansions to maintain their industry position

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Industry and Technology Snapshot
2.3. End-use Snapshot
2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing Focus on Water Testing
3.4.2. Legalization of Medical Cannabis and Growing Number of Cannabis Testing Laboratories
3.4.3. Increase in Outbreaks of Foodborne Illnesses
3.5. Market Restraint Analysis
3.5.1. High Capital Investment for Laboratory Proficiency Testing
3.6. Industry Analysis Tools
3.7. Market Opportunity Analysis, by Industry
3.7.1. Clinical Diagnostics
3.7.2. Pharmaceuticals
3.7.3. Microbiology
3.7.4. Cannabis
3.7.5. Others

Chapter 4. Industry Business Analysis
4.1. Laboratory Proficiency Testing Market: Industry Movement Analysis
4.2. Clinical Diagnostics
4.2.2. Clinical Chemistry
4.2.3. Immunochemistry
4.2.4. Hematology
4.2.5. Oncology
4.2.6. Molecular Diagnostics
4.2.6.2. PCR
4.2.6.3. Others
4.2.7. Coagulation
4.3. Pharmaceuticals
4.3.2. Biological Products
4.3.2.2. Vaccines
4.3.2.3. Blood
4.3.2.4. Tissues
4.4. Microbiology
4.4.2. Pathogen Testing
4.4.3. Sterility Testing
4.4.4. Endotoxin & Pyrogen Testing
4.4.5. Growth Promotion Testing
4.5. Cannabis
4.5.2. Medical
4.5.3. Non-Medical

Chapter 5. Technology Business Analysis
5.1. Laboratory Proficiency Testing Market: Technology Movement Analysis
5.2. Cell Culture
5.3. Spectrometry
5.4. Polymerase Chain Reaction
5.5. Chromatography
5.6. Immunoassays

Chapter 6. End-use Business Analysis
6.1. Laboratory Proficiency Testing Market: End-use Movement Analysis
6.2. Hospitals
6.3. Contract Research Organizations
6.4. Pharmaceutical & Biotechnology Companies
6.5. Academic & Research Institutes
6.6. Laboratories
6.6.2. Independent Laboratories
6.6.3. Specialty Laboratories

Chapter 7. Regional Business Analysis

Chapter 8. Competitive Landscape

  • LGC
  • Bio-Rad Laboratories, Inc
  • Randox Laboratories
  • QACS – The Challenge Test Laboratory
  • Merck KGaA
  • Weqas
  • BIPEA
  • NSI Lab Solutions
  • Absolute Standards, Inc.
  • INSTAND

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version